Moors & Cabot Inc. Has $3.19 Million Stake in Novartis AG (NVS)
Moors & Cabot Inc. lifted its position in Novartis AG (NYSE:NVS) by 11.4% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 38,195 shares of the company’s stock after buying an additional 3,894 shares during the quarter. Moors & Cabot Inc.’s holdings in Novartis AG were worth $3,190,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors have also recently modified their holdings of NVS. City Holding Co. raised its stake in Novartis AG by 4.6% during the 2nd quarter. City Holding Co. now owns 1,217 shares of the company’s stock valued at $102,000 after purchasing an additional 54 shares during the last quarter. Archford Capital Strategies LLC raised its stake in Novartis AG by 72.3% during the 1st quarter. Archford Capital Strategies LLC now owns 1,480 shares of the company’s stock valued at $110,000 after purchasing an additional 621 shares during the last quarter. Kernodle & Katon Asset Management Group LLC raised its stake in Novartis AG by 3.4% during the 1st quarter. Kernodle & Katon Asset Management Group LLC now owns 1,488 shares of the company’s stock valued at $111,000 after purchasing an additional 49 shares during the last quarter. Massey Quick & Co. LLC acquired a new position in Novartis AG during the 1st quarter valued at $119,000. Finally, North Star Investment Management Corp. raised its stake in Novartis AG by 1.0% during the 2nd quarter. North Star Investment Management Corp. now owns 1,542 shares of the company’s stock valued at $129,000 after purchasing an additional 16 shares during the last quarter. Institutional investors and hedge funds own 10.93% of the company’s stock.
Several equities analysts recently commented on the stock. BidaskClub cut shares of Novartis AG from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. Cowen and Company set a $90.00 target price on shares of Novartis AG and gave the company a “hold” rating in a research note on Wednesday, August 9th. J P Morgan Chase & Co reiterated a “neutral” rating on shares of Novartis AG in a research note on Monday, July 17th. Finally, Zacks Investment Research cut shares of Novartis AG from a “buy” rating to a “hold” rating in a research note on Friday. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and six have given a buy rating to the company’s stock. Novartis AG has an average rating of “Hold” and a consensus target price of $85.12.
TRADEMARK VIOLATION WARNING: “Moors & Cabot Inc. Has $3.19 Million Stake in Novartis AG (NVS)” was originally posted by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be viewed at https://www.dailypolitical.com/2017/10/07/moors-cabot-inc-has-3-19-million-stake-in-novartis-ag-nvs.html.
Shares of Novartis AG (NYSE:NVS) traded up 0.15% during midday trading on Friday, reaching $85.77. 818,819 shares of the company’s stock traded hands. Novartis AG has a 52-week low of $66.93 and a 52-week high of $86.90. The stock has a market cap of $200.95 billion, a price-to-earnings ratio of 31.31 and a beta of 0.73. The stock has a 50 day moving average of $84.84 and a 200-day moving average of $81.39.
Novartis AG (NYSE:NVS) last posted its earnings results on Tuesday, July 18th. The company reported $1.22 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.16 by $0.06. Novartis AG had a return on equity of 15.51% and a net margin of 13.52%. The company had revenue of $12.24 billion during the quarter, compared to the consensus estimate of $12.20 billion. During the same quarter last year, the firm earned $1.23 earnings per share. The company’s revenue was down 1.8% on a year-over-year basis. On average, equities research analysts expect that Novartis AG will post $4.75 EPS for the current year.
About Novartis AG
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).
Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.